Zobrazeno 1 - 10
of 328
pro vyhledávání: '"William W. Chin"'
Autor:
David Michelson, William W. Chin, Robert H. Dworkin, Roy Freeman, David N. Herrmann, Ralph Mazitschek, Rodica Pop-Busui, Aziz Shaibani, James Vornov, Melissa Jones, Matthew Jarpe, Brittany Hader, Theresa Viera, Michelle Hylan, Tim Kachmar, Simon Jones
Publikováno v:
PAIN Reports, Vol 8, Iss 6, p e1114 (2023)
Abstract. Introduction:. Current treatments for painful diabetic peripheral neuropathy (DPN) are insufficiently effective for many individuals and do not treat nonpain signs and symptoms. The enzyme histone deacetylase type 6 (HDAC6) may play a role
Externí odkaz:
https://doaj.org/article/43d645a10fbd4b539890e51d56390ee1
Autor:
Jonathan Kimmelman, William W. Chin, Holger Langhof, Susanne Wieschowski, Carole A Federico, Daniel Strech
Publikováno v:
British Journal of Pharmacology
Background and purpose Therapeutic area guidelines (TAGs) published by the EMA and the FDA offer guidance in planning the launch of a trial in a certain indication. We assessed and compared the guidance on preclinical efficacy of all available TAGs f
Autor:
Christopher P. Austin, Rajarshi Guha, Madhu Lal-Nag, Bart Trawick, Michelle R. Arkin, Timothy L. Foley, Philip W. Iversen, Jonathan B. Baell, Thomas D.Y. Chung, Zhuyin Li, Eric W. Sayers, Neely Gal-Edd, James McGee, Owen B. McManus, Hanguan Liu, Nathan P. Coussens, Xin Xu, Viswanath Devanaryan, Marilu A. Hoeppner, Matthew D. Hall, Bruce E. Bejcek, Vance Lemmon, Kyle R. Brimacombe, Jeffrey R. Weidner, Jayme L. Dahlin, Andrew D. Napper, Steven D. Kahl, Anton Simeonov, James Inglese, Robert Pacifici, G. Sitta Sittampalam, Lisa Minor, William W. Chin, Abigail Grossman, Julie McVey, Sam Michael, Douglas S. Auld, Stacy Lathrop, Menghang Xia, Terry L. Riss, Mary Jo Wildey, Marcie A. Glicksman, Joseph V. Haas, Stephen C. Kales, O. Joseph Trask
Publikováno v:
Clinical and Translational Science. 11:461-470
The Assay Guidance Manual (AGM) is an eBook of best practices for the design, development, and implementation of robust assays for early drug discovery. Initiated by pharmaceutical company scientists, the manual provides guidance for designing a "tes
Autor:
William W. Chin
Publikováno v:
British Journal of Medicine and Medical Research. 15:1-7
Publikováno v:
New England Journal of Medicine
The Human Touch Responses to the Covid-19 pandemic by stakeholders throughout the health care ecosystem are contributing to rapid innovation, including the development of new equipment and drugs. L...
Autor:
Sören Sievers, William W. Chin, Jonathan Kimmelman, Daniel Strech, Carole A Federico, Susanne Wieschowski
Publikováno v:
PLoS Biology, Vol 16, Iss 4, p e2004879 (2018)
PLoS Biology
PLoS Biology
Human protection policies require favorable risk–benefit judgments prior to launch of clinical trials. For phase I and II trials, evidence for such judgment often stems from preclinical efficacy studies (PCESs). We undertook a systematic investigat
Autor:
Lu Yu, Ronny Lesmana, Toshiharu Iwasaki, Yu Xiong, Ming Xu, William W. Chin, Noriaki Shimokawa, Noriyuki Koibuchi
Publikováno v:
Endocrinology. 156:1565-1576
To study the role of the thyroid hormone (TH) in cerebellar development, we generated transgenic mice expressing a dominant-negative TH receptor (TR) in cerebellar Purkinje cells. A mutant human TRβ1 (G345R), which binds to the TH-response element b
Autor:
William W. Chin
Publikováno v:
New England Journal of Medicine. 373:1799-1801
Even with many new therapeutic options, the proportion of health care spending devoted to retail prescription medications remains about the same as it was in 1960. Relying on competitive markets to set drug prices and encourage innovation seems to be
Autor:
Frank D. Sistare, John-Michael Sauer, John A. Wagner, Tanja S. Zabka, Gary J. Kelloff, Gabriela Lavezzari, William W. Chin, Rajesh Ranganathan, David Wholley, Martha Brumfield, Steven C. Hoffmann, Jiri Aubrecht, Linda S. Brady, Joseph P. Menetski, Chris Leptak
Publikováno v:
Science translational medicine. 9(417)
Biomarkers can facilitate all aspects of the drug development process. However, biomarker qualification-the use of a biomarker that is accepted by the U.S. Food and Drug Administration-needs a clear, predictable process. We describe a multistakeholde
Autor:
Flagship Ventures, Steven E. Weinberger, Steven K. Galson, Samuel R. Nussbaum, Michelle McMurry-Heath, Marc M. Boutin, John J. Orloff, Michael Rosenblatt, Christopher P. Austin, Janet Woodcock, William W. Chin, Sachin H. Jain
Publikováno v:
NAM Perspectives. 6